MCC19704 (Non Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this research to learn if we can improve the health of people diagnosed with stage III Lung Cancer.

What is the Condition Being Studied?

Lung Cancer (non small cell lung cancer)

Who Can Participate in the Study?

- Adults Diagnosed with Stage III Lung Cancer
- Have not received more than 1 cycle of chemotherapy
- Have not received immunotherapy for lung cancer before

Age Group

What is Involved?

If you choose to join this study you will:
- Complete normal radiation therapy every day for 6 weeks (M-F)
- Get the study drug (Ipilimumab) when you get radiation
- Get the other study drug (Nivolumab) once a month after radiation
- Continue treatment if it is helping up to 12 cycles

Study Details

Full Title
Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable NSCLC. MCC 19704.
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00101793
NCT: NCT03663166
Phase I/II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center